Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gentry, P. R.
Right arrow Articles by Clewell, H. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gentry, P. R.
Right arrow Articles by Clewell, H. J., III
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Toxicological Sciences 70, 120-139 (2002)
Copyright © 2002 by the Society of Toxicology

RISK ASSESSMENT

An Approach for the Quantitative Consideration of Genetic Polymorphism Data in Chemical Risk Assessment: Examples with Warfarin and Parathion

P. Robinan Gentry*,1, C. Eric Hack*, Lynne Haber{dagger}, Andrew Maier{dagger} and Harvey J. Clewell, III*

* ENVIRON International Corporation, 602 East Georgia Avenue, Ruston, Louisiana 71270; and {dagger} Toxicology Excellence for Risk Assessment, Cincinnati, Ohio 45223

ABSTRACT

In recent years, a great deal of research has been conducted to identify genetic polymorphisms. One focus has been to characterize variability in metabolic enzyme systems that could impact internal doses of pharmaceuticals or environmental pollutants. Methods are needed for using this metabolic information to estimate the resulting variability in tissue doses associated with chemical exposure. We demonstrate here the use of physiologically based pharmacokinetic (PBPK) modeling in combination with Monte Carlo analysis to incorporate information on polymorphisms into the analysis of toxicokinetic variability. Warfarin and parathion were used as case studies to demonstrate this approach. Our results suggest that polymorphisms in the PON1 gene, that give rise to allelic variants of paraoxonase, which is involved in the metabolism of paraoxon (a metabolite of parathion), make only a minor contribution to the overall variability in paraoxon tissue dose, while polymorphisms in the CYP2C9 gene, which gives rise to allelic variants of the major metabolic enzyme for warfarin, account for a significant portion of the overall variability in (S)-warfarin tissue dose. These analyses were used to estimate chemical-specific adjustment factors (CSAFs) for the human variability in toxicokinetics for both parathion and warfarin. Implications of alternatives in the calculation of CSAFs are explored. Key decision points for applying the PBPK-Monte Carlo approach to evaluate toxicokinetic variability for other chemicals are also discussed.

Key Words: genetic polymorphisms; physiologically based pharmacokinetic (PBPK) modeling; Monte Carlo analysis; toxicokinetic variability; warfarin; parathion; risk assessment.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Toxicol SciHome page
J. L. C. M. Dorne and A. G. Renwick
The Refinement of Uncertainty/Safety Factors in Risk Assessment by the Incorporation of Data on Toxicokinetic Variability in Humans
Toxicol. Sci., July 1, 2005; 86(1): 20 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
L. G. Sultatos, G. M. Pastino, C. A. Rosenfeld, and E. J. Flynn
Incorporation of the Genetic Control of Alcohol Dehydrogenase into a Physiologically Based Pharmacokinetic Model for Ethanol in Humans
Toxicol. Sci., March 1, 2004; 78(1): 20 - 31.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.